Genesis Genetics

genesisgenetics.org

Genesis Genetics is the leading global provider of Preimplantation Genetic Diagnosis (PGD) & Preimplantation Genetic Screening (PGS) - providing expert laboratory services for many of the most respected in vitro fertilization (IVF) centers across the country and throughout the world. Founded by a group of world-renowned scientists, Genesis Genetics has pioneered the clinical practice of preimplantation testing of embryos for inherited genetic abnormalities, and our doctors and scientists have performed many of the first and continually successful cases in the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

PSYCHECEUTICAL COMPLETES ACQUISITION BY BLUE WATER VENTURES INTERNATIONAL

Blue Water Ventures International | January 20, 2022

news image

Psycheceutical, Inc. a biotechnology company dedicated to the development and commercialization of psychedelic medicines, announced the company has been fully acquired by Blue Water Ventures International, Inc. “We are thrilled that this deal has closed and that Psycheceutical is now a wholly-owned subsidiary of a publicly-listed company and has secured important near-term capital to pursue our growth plans. We will immediately begin the next steps of o...

Read More

CELL AND GENE THERAPY

SYSMEX AND THINKCYTE HAVE ENTERED INTO AN AGREEMENT FOR JOINT DEVELOPMENT AND CAPITAL ALLIANCE

Sysmex Corporation | May 17, 2021

news image

Sysmex Corporation and ThinkCyte, Inc. announced today the signing of joint development and investment agreements for the commercialization of an AI-based cell analysis technology in May 2021. The development of novel testing and diagnostic technologies of high clinical utility is being pursued to improve the precision of diagnoses and maximize treatment as healthcare becomes more accurate and personalized at an increased pace - in combination with the advancement of technology. M...

Read More

MEDICAL

DXTERITY DIAGNOSTICS ANNOUNCES THE LAUNCH OF IFN-1 TEST FOR LUPUS

DxTerity | June 13, 2022

news image

DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus. DxTerity's test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE disease severity and prognosis. High IFN-1 levels have been shown to lead to higher likelihood of disease severity and an incr...

Read More

DIAGNOSTICS

NEOGEN® AND GENCOVE LAUNCH INFINISEEK™ -- THE FIRST WHOLE GENOME AND GENOTYPING SEQUENCING SOLUTION FOR CATTLE BREEDERS

NEOGEN | May 16, 2022

news image

NEOGEN® Corporation (NASDAQ: NEOG) and Gencove, the leading low-pass whole genome sequencing and analysis software company, today announced the launch of InfiniSEEK™, an innovative, cost-effective solution for whole genome sequencing and targeted SNP analysis. Combining NEOGEN's world-class genomic solutions and services with Gencove's low-pass sequencing and analytics software, the solution can deliver genomic insights to help advance cattle breeding programs wo...

Read More
news image

INDUSTRIAL IMPACT

PSYCHECEUTICAL COMPLETES ACQUISITION BY BLUE WATER VENTURES INTERNATIONAL

Blue Water Ventures International | January 20, 2022

Psycheceutical, Inc. a biotechnology company dedicated to the development and commercialization of psychedelic medicines, announced the company has been fully acquired by Blue Water Ventures International, Inc. “We are thrilled that this deal has closed and that Psycheceutical is now a wholly-owned subsidiary of a publicly-listed company and has secured important near-term capital to pursue our growth plans. We will immediately begin the next steps of o...

Read More
news image

CELL AND GENE THERAPY

SYSMEX AND THINKCYTE HAVE ENTERED INTO AN AGREEMENT FOR JOINT DEVELOPMENT AND CAPITAL ALLIANCE

Sysmex Corporation | May 17, 2021

Sysmex Corporation and ThinkCyte, Inc. announced today the signing of joint development and investment agreements for the commercialization of an AI-based cell analysis technology in May 2021. The development of novel testing and diagnostic technologies of high clinical utility is being pursued to improve the precision of diagnoses and maximize treatment as healthcare becomes more accurate and personalized at an increased pace - in combination with the advancement of technology. M...

Read More
news image

MEDICAL

DXTERITY DIAGNOSTICS ANNOUNCES THE LAUNCH OF IFN-1 TEST FOR LUPUS

DxTerity | June 13, 2022

DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus. DxTerity's test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE disease severity and prognosis. High IFN-1 levels have been shown to lead to higher likelihood of disease severity and an incr...

Read More
news image

DIAGNOSTICS

NEOGEN® AND GENCOVE LAUNCH INFINISEEK™ -- THE FIRST WHOLE GENOME AND GENOTYPING SEQUENCING SOLUTION FOR CATTLE BREEDERS

NEOGEN | May 16, 2022

NEOGEN® Corporation (NASDAQ: NEOG) and Gencove, the leading low-pass whole genome sequencing and analysis software company, today announced the launch of InfiniSEEK™, an innovative, cost-effective solution for whole genome sequencing and targeted SNP analysis. Combining NEOGEN's world-class genomic solutions and services with Gencove's low-pass sequencing and analytics software, the solution can deliver genomic insights to help advance cattle breeding programs wo...

Read More